January 17, 2023 16:05 ET ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company’s Management will provide a corporate update and participate in one-on-one […]
January 09, 2023 08:00 ET -Clinical trial is being conducted at St. James’s University Hospital, United Kingdom, in collaboration with the University of Leeds- ROCKVILLE, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas
December 01, 2022 08:00 ET ROCKVILLE, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company’s Management will participate in the following upcoming investor conferences in
Theriva™ Biologics to Participate in Upcoming Investor Conferences Read More »
November 10, 2022 07:00 ET -Conference call to be held on Friday, November 11 at 8:30 a.m. ET- ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today
November 10, 2022 16:45 ET –Reported encouraging clinical data supporting the differentiated mode-of action of Theriva’s novel oncolytic adenovirus (OV) platform– –Received clearance from the Federal Drug Administration (FDA) and Spanish Competent Authority (AEMPS) for the planned Phase 2 clinical trial of systemically administered VCN-01 in Pancreatic Ductal Adenocarcinoma (PDAC) patients– –Reported positive safety and
November 03, 2022 08:00 ET – Initiation of Cohort 2 Follows a Positive Review of Safety and Pharmacokinetic (PK) Data from Cohort 1 by an Independent Data and Safety Monitoring Committee – – Cohort 2 Patient Dosing Highlights Momentum Across the Theriva Oncology-Focused Clinical Pipeline – ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) — Theriva
November 03, 2022 16:05 ET ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, November 10,
-Webinar to feature presentation from immunotherapy experts Michael Aaron Morse, M.D., and Arsen Osipov, M.D., on Monday, November 7th at 11 a.m. ET- October 31, 2022 08:00 ET ROCKVILLE, Md., Oct. 31, 2022 (GLOBE NEWSWIRE) — Theriva Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat
– Data to be featured in an oral presentation highlighting the encouraging biological activity of VCN-01 treatment in combination with durvalumab- October 24, 2022 08:00 ET ROCKVILLE, Md., Oct. 24, 2022 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related
Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administration October 12, 2022 08:00 ET ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) — Theriva Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”) is the new name of Synthetic Biologics, Inc. (NYSE American: SYN). The new name, logo and
Synthetic Biologics Rebrands as Theriva Biologics Read More »
